Stay updated with breaking news from Nasdaq Trda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […]
- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving...
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total value of $160,132.14. Following the sale, the chief financial officer now owns 49,571 shares in the company, […]
Entrada Therapeutics (NASDAQ:TRDA – Free Report) had its price objective reduced by HC Wainwright from $25.00 to $20.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Entrada Therapeutics Stock Performance Shares of NASDAQ:TRDA opened at $12.97 on Monday. The firm has a market capitalization […]
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $16.67, but opened at $15.90. Entrada Therapeutics shares last traded at $15.47, with a volume of 5,380 shares. Analyst Upgrades and Downgrades Separately, HC Wainwright reiterated a “buy” rating and […]